SOCS1 Haploinsufficiency Presenting as Severe Enthesitis, Bone Marrow Hypocellularity, and Refractory Thrombocytopenia in a Pediatric Patient with Subsequent Response to JAK Inhibition.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
11 2022
Historique:
received: 25 05 2022
accepted: 09 08 2022
pubmed: 18 8 2022
medline: 30 11 2022
entrez: 17 8 2022
Statut: ppublish

Résumé

Haploinsufficiency of suppressor of cytokine signaling 1 (SOCS1) is a recently discovered autoinflammatory disorder with significant rheumatologic, immunologic, and hematologic manifestations. Here we report a case of SOCS1 haploinsufficiency in a 5-year-old child with profound arthralgias and immune-mediated thrombocytopenia unmasked by SARS-CoV-2 infection. Her clinical manifestations were accompanied by excessive B cell activity, eosinophilia, and elevated IgE levels. Uniquely, this is the first report of SOCS1 haploinsufficiency in the setting of a chromosomal deletion resulting in complete loss of a single SOCS1 gene with additional clinical findings of bone marrow hypocellularity and radiologic evidence of severe enthesitis. Immunologic profiling showed a prominent interferon signature in the patient's peripheral blood mononuclear cells, which were also hypersensitive to stimulation by type I and type II interferons. The patient showed excellent clinical and functional laboratory response to tofacitinib, a Janus kinase inhibitor that disrupts interferon signaling. Our case highlights the need to utilize a multidisciplinary diagnostic approach and consider a comprehensive genetic evaluation for inborn errors of immunity in patients with an atypical immune-mediated thrombocytopenia phenotype.

Identifiants

pubmed: 35976468
doi: 10.1007/s10875-022-01346-x
pii: 10.1007/s10875-022-01346-x
pmc: PMC9381392
doi:

Substances chimiques

Suppressor of Cytokine Signaling 1 Protein 0
Suppressor of Cytokine Signaling Proteins 0
Interferons 9008-11-1
SOCS1 protein, human 0

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1766-1777

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007622
Pays : United States
Organisme : National Institute of Health / National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ID : K08-AR074562

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Pediatr Rev. 2019 May;40(5):229-242
pubmed: 31043442
FASEB J. 2011 Mar;25(3):863-74
pubmed: 21084693
Nat Rev Drug Discov. 2017 Dec 28;17(1):78
pubmed: 29282366
Leukemia. 1999 Jun;13(6):926-34
pubmed: 10360382
J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78
pubmed: 26371839
J Clin Immunol. 2018 Apr;38(3):320-329
pubmed: 29675737
J Interferon Cytokine Res. 2018 Apr;38(4):171-185
pubmed: 29638206
Front Immunol. 2021 Aug 05;12:680334
pubmed: 34421895
J Allergy Clin Immunol. 2020 Nov;146(5):1194-1200.e1
pubmed: 32853638
Pharmaceutics. 2022 May 06;14(5):
pubmed: 35631587
Nat Commun. 2018 Apr 19;9(1):1558
pubmed: 29674694
Nat Rev Immunol. 2018 Sep;18(9):545-558
pubmed: 29921905
Genes Immun. 2007 Jan;8(1):21-7
pubmed: 17093501
Inflammation. 2018 Aug;41(4):1557-1567
pubmed: 29907905
Nature. 2020 Jul;583(7814):90-95
pubmed: 32499645
Blood. 2001 Jan 1;97(1):221-6
pubmed: 11133764
Arthritis Res Ther. 2019 Aug 2;21(1):183
pubmed: 31375130
J Exp Med. 2003 Sep 15;198(6):937-45
pubmed: 12975458
J Clin Exp Hematop. 2018;58(2):68-86
pubmed: 29998978
Nat Commun. 2020 Oct 21;11(1):5341
pubmed: 33087723
Sci Rep. 2017 Jan 06;7:39904
pubmed: 28057926
Front Immunol. 2016 Aug 29;7:330
pubmed: 27621733
Front Med (Lausanne). 2021 Jun 24;8:613192
pubmed: 34249957
Blood. 2019 Jul 4;134(1):9-21
pubmed: 30940614
J Clin Immunol. 2019 Aug;39(6):577-591
pubmed: 31250335
Blood Coagul Fibrinolysis. 2015 Jun;26(4):368-72
pubmed: 25688463

Auteurs

Thomas F Michniacki (TF)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. tmich@med.umich.edu.

Kelly Walkovich (K)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.

Lauren DeMeyer (L)

Division of Genetics, Metabolism & Genomic Medicine, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.

Nadine Saad (N)

Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.

Mark Hannibal (M)

Division of Genetics, Metabolism & Genomic Medicine, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.

Matthew L Basiaga (ML)

Division of Pediatric Rheumatology, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.

Kelly K Horst (KK)

Division of Pediatric Radiology, Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Smriti Mohan (S)

Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.

Liang Chen (L)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Kailey Brodeur (K)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Yan Du (Y)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

David Frame (D)

Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.

Sandra Ngo (S)

Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.

Jillian Simoneau (J)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.

Noah Brown (N)

Department of Pathology, University of Michigan, Ann Arbor, MI, USA.

Pui Y Lee (PY)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH